Pacira BioSciences, Inc. (PCRX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PCRX Revenue Growth
Revenue Breakdown (FY 2025)
PCRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PCRX Revenue Analysis (2014–2025)
As of May 8, 2026, Pacira BioSciences, Inc. (PCRX) generated trailing twelve-month (TTM) revenue of $734.9 million, reflecting solid growth of +5.0% year-over-year. The most recent quarter (Q1 2026) recorded $177.4 million in revenue, down 9.9% sequentially.
Looking at the longer-term picture, PCRX's 5-year compound annual growth rate (CAGR) stands at +11.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $726.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows PCRX's business is primarily driven by Product (51%), EXPAREL (40%), and ZILRETTA (8%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRGO (-3.6% YoY), BHC (+8.5% YoY), and SUPN (+16.3% YoY), PCRX has underperformed the peer group in terms of revenue growth. Compare PCRX vs PRGO →
PCRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCRXCurrent | $735M | +5.0% | +11.1% | 4.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 BHC | $10.4B | +8.5% | +5.4% | 21.3% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
PCRX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $726.4M | +3.6% | $576.7M | 79.4% | $33.3M | 4.6% |
| 2024 | $701.0M | +3.9% | $530.5M | 75.7% | $-73,371,000 | -10.5% |
| 2023 | $675.0M | +1.2% | $490.3M | 72.6% | $87.7M | 13.0% |
| 2022 | $666.8M | +23.1% | $467.5M | 70.1% | $60.0M | 9.0% |
| 2021 | $541.5M | +26.0% | $401.3M | 74.1% | $89.9M | 16.6% |
| 2020 | $429.6M | +2.0% | $312.3M | 72.7% | $46.4M | 10.8% |
| 2019 | $421.0M | +24.8% | $314.3M | 74.7% | $10.5M | 2.5% |
| 2018 | $337.3M | +17.7% | $250.4M | 74.3% | $15.9M | 4.7% |
| 2017 | $286.6M | +3.7% | $198.7M | 69.3% | $-24,937,000 | -8.7% |
| 2016 | $276.4M | +11.0% | $166.3M | 60.2% | $-32,024,000 | -11.6% |
See PCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
Is PCRX's revenue growth accelerating or slowing?
PCRX revenue growth slowed to +5.0%, below the 5-year CAGR of +11.1%. TTM revenue is $735M. The deceleration marks a shift from historical growth rates.
What is PCRX's long-term revenue growth rate?
Pacira BioSciences, Inc.'s 5-year revenue CAGR of +11.1% reflects the variable expansion pattern. Current YoY growth of +5.0% is near this long-term average.
How is PCRX's revenue distributed by segment?
PCRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.